Neurofibromatosis Type 2 (NF2) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Neurofibromatosis Type 2 (NF2) Market Outlook

Thelansis’s “Neurofibromatosis Type 2 (NF2) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neurofibromatosis Type 2 (NF2) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Neurofibromatosis Type 2 (NF2) Overview

Neurofibromatosis type 2 (NF2) is an autosomal-dominant tumor-prone disorder predisposed to nerve system tumors. Bilateral vestibular schwannoma (VS) is pathognomonic or the disease, whereas schwannoma at other locations, meningiomas, ependymomas, and early onset lenticular opacities are frequently associated with the phenotypes. Vestibular schwannoma-related symptoms were seen in most of the patients (55%), followed by ophthalmological symptoms/abnormalities (45%) and cutaneous features (38%). About 40% of all patients were monosymptomatic, 55% showed ≥2 symptoms at symptom onset, and ~5% were asymptomatic. Including polysymptomatic occurrence and symptomatic and asymptomatic findings, 62% of young patients exhibit ophthalmological abnormalities, followed by cutaneous findings (43%). Most people with NF2 develop symptoms in the late teen and early adult years, although about 10% of people develop symptoms during late childhood. The most common symptoms of NF2 include ringing in the ears (tinnitus), gradual hearing loss, and balance problems.

• Neurofibromatosis type 2 (NF2) incidence ranges from 1 to 1.2 cases in 40,000 live birth Neurofibromatosis type 2 (NF2).

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2021-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: